Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 5
2003 5
2004 9
2005 3
2006 3
2007 7
2008 5
2009 5
2010 7
2011 5
2012 5
2013 5
2014 7
2015 3
2016 7
2017 7
2018 6
2019 2
2020 5
2021 6
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Results by year

Filters applied: . Clear all
Page 1
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, Kulke MH, Baird RD, Prabhu JS, Carbone D, Pecoraro C, Teh DBL, Sethi G, Cavalieri V, Lin KH, Javidi-Sharifi NR, Toska E, Davids MS, Brown JR, Diana P, Stebbing J, Fruman DA, Kumar AP. Glaviano A, et al. Among authors: fruman da. Mol Cancer. 2023 Aug 18;22(1):138. doi: 10.1186/s12943-023-01827-6. Mol Cancer. 2023. PMID: 37596643 Free PMC article. Review.
The PI3K Pathway in Human Disease.
Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. Fruman DA, et al. Cell. 2017 Aug 10;170(4):605-635. doi: 10.1016/j.cell.2017.07.029. Cell. 2017. PMID: 28802037 Free PMC article. Review.
YAP-mediated mechanotransduction tunes the macrophage inflammatory response.
Meli VS, Atcha H, Veerasubramanian PK, Nagalla RR, Luu TU, Chen EY, Guerrero-Juarez CF, Yamaga K, Pandori W, Hsieh JY, Downing TL, Fruman DA, Lodoen MB, Plikus MV, Wang W, Liu WF. Meli VS, et al. Among authors: fruman da. Sci Adv. 2020 Dec 4;6(49):eabb8471. doi: 10.1126/sciadv.abb8471. Print 2020 Dec. Sci Adv. 2020. PMID: 33277245 Free PMC article.
Targeting the Mevalonate Pathway in Cancer.
Juarez D, Fruman DA. Juarez D, et al. Among authors: fruman da. Trends Cancer. 2021 Jun;7(6):525-540. doi: 10.1016/j.trecan.2020.11.008. Epub 2021 Jan 6. Trends Cancer. 2021. PMID: 33358111 Free PMC article. Review.
Idelalisib--a PI3Kδ inhibitor for B-cell cancers.
Fruman DA, Cantley LC. Fruman DA, et al. N Engl J Med. 2014 Mar 13;370(11):1061-2. doi: 10.1056/NEJMe1400055. N Engl J Med. 2014. PMID: 24620870 Free PMC article. No abstract available.
Targeting mTOR for the treatment of B cell malignancies.
Lee JS, Vo TT, Fruman DA. Lee JS, et al. Among authors: fruman da. Br J Clin Pharmacol. 2016 Nov;82(5):1213-1228. doi: 10.1111/bcp.12888. Epub 2016 Mar 3. Br J Clin Pharmacol. 2016. PMID: 26805380 Free PMC article. Review.
109 results